Benign vs Malignant Brain Tumors: Key Differences

Nobody explains this properly. So people walk out of consultations thinking benign means safe and malignant means it’s over. Neither is quite right.

Here’s what benign actually means the tumor stays put. It doesn’t invade the tissue around it. It won’t pack up and travel to your liver or your lungs. That’s it. That’s the whole definition. It says nothing about how big the thing is, what it’s sitting next to, whether it’s pressing on something that controls your breathing or your vision or your ability to speak. A benign tumor on your brainstem doing damage to every structure around it is still benign. And a small malignant tumor caught early in an area a surgeon can actually reach that’s a completely different situation from what most families imagine when they hear malignant. The label is where the conversation starts. Not where it ends.

Dr. Gurneet Singh Sawhney is a neurosurgeon at Fortis Hospital Mumbai. Eighteen years of this. He’s sat with families after every kind of brain tumor diagnosis and the first thing he usually has to do is unpack what the word actually means for their specific case because what most people think it means and what it actually means are pretty far apart.

Benign sometimes surgery really is the whole story: Full resection, clean margins, nothing obvious left behind. For a well-positioned meningioma that goes to plan no radiotherapy, no chemotherapy, just follow-up scans. And if those stay clear, it’s over. That outcome is real and it happens regularly at experienced centres. But. Incompletely resected benign tumors come back. Some of them come back aggressively. And certain locations in the skull base, near major venous sinuses, wrapped around cranial nerves make complete removal genuinely impossible no matter how the pathology reads. Benign doesn’t make the location cooperative.

Malignant the treatment doesn’t stop when the surgery does: Maximal safe resection first. Then radiotherapy. Then chemotherapy. For glioblastoma that’s the Stupp protocol concurrent chemoradiation and then months of adjuvant temozolomide. Surgery knocks back the visible tumor. But cells surgery couldn’t follow are already sitting in the surrounding tissue. They’re what drives recurrence. And they will. The surveillance doesn’t stop either. Years of imaging. It’s a long road and families deserve to know that going in rather than discovering it after.

As a Neurosurgeon in Mumbai who handles both ends of this every week, Dr. Sawhney doesn’t let the label do the whole job. Grade, location, what surgery can realistically achieve, what comes after that’s the actual conversation.

A patient who leaves with the label and not much else isn’t really equipped for what’s coming.

Dr. Sawhney trained under Prof. Taira at Tokyo Women’s Medical University that’s a full functional neurosurgery fellowship, not a rotation. Then under Prof. Sugano at Juntendo University for epilepsy surgery. Two separate fellowships at centres doing complex intracranial work seriously. Back at Fortis Hospital Mulund West, the pre-surgical workup isn’t just the MRI report, functional imaging, tractography where it matters, neuropsychological baseline before the approach is fixed. Awake craniotomy for cases near the eloquent cortex. And after surgery the same team handles adjuvant therapy coordination, surveillance schedule, follow-up. Because whether the diagnosis is benign or malignant, a family sitting in that consultation room deserves an answer that actually applies to them, not a general definition with a follow-up appointment three months later.